Alfred E. Tiefenbacher (Germany)

Alfred E. Tiefenbacher (Germany) is a Hamburg-based pharmaceutical company operating as part of the Tiefenbacher Group, a 100% family-owned healthcare group. The company describes itself as a purpose-driven healthcare provider delivering best-in-class solutions across the entire pharmaceutical value chain, with the stated aim of making medicines more affordable, more available and better than before. Its business spans the full life cycle of a pharmaceutical product: it develops, manufactures and registers value-added generics and innovative medicines, including high-potent drugs, and licenses the resulting dossiers out to marketing partners around the world. The company positions itself as a B2B partner rather than a consumer-facing drug brand. It supplies marketing authorizations, dossiers and finished products to pharmaceutical companies and distribution partners, and it reports a portfolio of more than 180 products across a wide range of therapeutic categories and dosage forms. Its disease areas include oncology, respiratory, neuroscience, cardiovascular, renal and metabolism, immunology, hepatology and dermatology, infectious diseases and ophthalmology. Dosage forms range from tablets, capsules, powders, drops, inhalers and transdermal patches to eye drops and additional medical devices. According to its own corporate communications, the Tiefenbacher Group employs over 900 people worldwide, serves more than 500 million patients every year, has obtained more than 15,000 marketing authorizations, sells products in over 80 countries and works with more than 150 marketing partners. The group also cites an in-house production capacity of more than 3 billion units per year and a pipeline of more than 40 affordable, innovative medicines and e-health solutions. These figures are company-reported and should be treated as self-described rather than independently audited. The company's model is built on integrated services that run from initial idea to patient: research and market intelligence, development, manufacturing, registration and licensing-out. It emphasizes value-added medicines (VAM) and innovative formulations, product differentiation, sustainable packaging and complex launches in more than 80 countries. Its own laboratories and manufacturing sites are presented as the foundation of efficient supply chains. Ownership remains private and family-based, and the group is headquartered in Hamburg, Germany.

Alfred E. Tiefenbacher (Germany) is a Hamburg-based pharmaceutical company that forms part of the Tiefenbacher Group, described in its own corporate materials as a 100% family-owned healthcare company. The group presents itself as a purpose-driven organization whose mission is to make medicines more affordable, more available and better than before. While the precise founding date is not established in the available evidence, the company has grown into an international B2B pharmaceutical player with operations spanning development, manufacturing, registration and licensing. The company's historical development is closely tied to its integrated business model. Rather than operating primarily as a consumer-facing pharmaceutical brand, it built its position by developing dossiers and registering medicines that are then licensed out to marketing partners worldwide. This licensing-out model, combined with in-house laboratories and manufacturing sites, allowed the group to scale its portfolio across numerous therapeutic areas and dosage forms. The company reports that it has obtained more than 15,000 marketing authorizations and that its products are sold in over 80 countries through more than 150 marketing partners. Over time, the group expanded its capabilities to include high-potent drugs, value-added medicines and innovative formulations, as well as sustainable packaging. It also reports a pipeline of more than 40 affordable, innovative medicines and e-health solutions. Its stated production capacity exceeds 3 billion units per year, and it says it serves more than 500 million patients annually. These figures are drawn from the company's own communications and are not independently verified in the available evidence. The company remains privately held and family-owned, with headquarters in Hamburg, Germany. Its corporate identity emphasizes a purpose-driven approach to healthcare, patient-centered development and the goal of improving access to medicines globally. The Tiefenbacher Group employs over 900 people worldwide, according to its own reporting.

B2B pharmaceutical partner offering affordable, value-added and innovative medicines across the full product life cycle, from development and manufacturing to registration and licensing-out.

• Value-added generics

  Affordable generic medicines with added value, developed and registered for global markets.

• Innovative medicines

  Innovative formulations and medicines, including high-potent drugs, licensed to marketing partners.

• Value-added medicines (VAM)

  Differentiated products designed to better meet patient needs, such as improved absorption or fixed-dose combinations.

• Dossiers and marketing authorizations

  In-house-developed regulatory dossiers licensed out to partners worldwide.

1. 1Tiefenbacher Pharmaceuticals | Pioneering Healthcaretiefenbacher-pharmaceuticals.com
2. 2About us - Tiefenbacher Pharmaceuticals I Pioneering Healthcaretiefenbacher-pharmaceuticals.com
3. 3Our Products - Tiefenbacher Pharmaceuticals I Pioneering Healthcaretiefenbacher-pharmaceuticals.com
4. 4Alfred E. Tiefenbacher (Germany) - Wikidatawikidata.org